Amedeo Smart

Free Medical Literature Service


 

Amedeo

Gastric Cancer

  Free Subscription

Articles published in
Anticancer Res
    November 2021
  1. CHANG K, Song B, DO IG, Koo DH, et al
    Venous Invasion and Perineural Invasion as Upstaging and Poor Prognostic Factors in N0 Gastric Cancers.
    Anticancer Res. 2021;41:5803-5810.
    >> Share

  2. OKUBO K, Arigami T, Matsushita D, Uenosono Y, et al
    The Clinical Significance of CA19-9 and Tumor Size Ratios for Predicting Prognosis After Conversion Surgery in Patients With Stage IV Gastric Cancer.
    Anticancer Res. 2021;41:5643-5649.
    >> Share

  3. AOYAMA T, Nakazono M, Segami K, Nagasawa S, et al
    Safety and Feasibility of Gastrectomy for Gastric Cancer in Patients Receiving Antiplatelet and/or Anticoagulation Treatment.
    Anticancer Res. 2021;41:5605-5610.
    >> Share

  4. MA YE, Liang X, Liu LI, Gao D, et al
    Survival Response of Patients With Gastric Cancer Treated With Regional Arterial-Perfusion Chemotherapy Is Correlated With Borrmann Classification.
    Anticancer Res. 2021;41:5507-5515.
    >> Share

  5. TSUJIYA Y, Yamamori M, Hasegawa AI, Yamamoto Y, et al
    Telmisartan Exerts Cytotoxicity in Scirrhous Gastric Cancer Cells by Inducing G0/G1 Cell Cycle Arrest.
    Anticancer Res. 2021;41:5461-5468.
    >> Share

    September 2021
  6. KOH SA, Lee KH
    HGF-mediated Up-regulation of PHLDA2 Is Associated With Apoptosis in Gastric Cancer.
    Anticancer Res. 2021;41:4377-4385.
    >> Share

  7. CHEN HY, Yang MD, Chou YC, Ma YS, et al
    Ouabain Suppresses Cell Migration and Invasion in Human Gastric Cancer AGS Cells Through the Inhibition of MMP Signaling Pathways.
    Anticancer Res. 2021;41:4365-4375.
    >> Share

  8. WEIDLE UH, Birzele F, Auslaender S, Brinkmann U, et al
    Down-regulated MicroRNAs in Gastric Carcinoma May Be Targets for Therapeutic Intervention and Replacement Therapy.
    Anticancer Res. 2021;41:4185-4202.
    >> Share

    August 2021
  9. HAN SH, Han JH, Han SH, Kim HS, et al
    Fixation Using Carnoy's Solution Enables Detection of More Lymph Nodes After Gastrectomy for Gastric Cancer.
    Anticancer Res. 2021;41:3949-3953.
    >> Share

  10. NAKAZAWA N, Sohda M, Yamaguchi A, Watanabe T, et al
    An Elevated Serum Lactate Dehydrogenase-to-albumin Ratio Is a Useful Poor Prognostic Predictor of Nivolumab in Patients With Gastric Cancer.
    Anticancer Res. 2021;41:3925-3931.
    >> Share

  11. MATSUMOTO T, Toya R, Shimohigashi Y, Watakabe T, et al
    Plan Quality Comparisons Between 3D-CRT, IMRT, and VMAT Based on 4D-CT for Gastric MALT Lymphoma.
    Anticancer Res. 2021;41:3941-3947.
    >> Share

    July 2021
  12. HYUN CL, Park SJ, Kim HS, Song HJ, et al
    The Intestinal Stem Cell Marker SMOC2 Is an Independent Prognostic Marker Associated With Better Survival in Gastric Cancer.
    Anticancer Res. 2021;41:3689-3698.
    >> Share

  13. HATORI S, Sakamaki K, Yokohori T, Kimura Y, et al
    Clinical Significance of PLA2G2A Expression in Gastric Cancer Patients who Receive Gastrectomy and Adjuvant S-1.
    Anticancer Res. 2021;41:3583-3588.
    >> Share

  14. KULIG P, Nowakowski P, Sierzega M, Pach R, et al
    Analysis of Prognostic Factors Affecting Short-term and Long-term Outcomes of Gastric Cancer Resection.
    Anticancer Res. 2021;41:3523-3534.
    >> Share

  15. AKANDA MR, Park JS, Noh MG, Ha GH, et al
    TACC3 Promotes Gastric Carcinogenesis by Promoting Epithelial-mesenchymal Transition Through the ERK/Akt/cyclin D1 Signaling Pathway.
    Anticancer Res. 2021;41:3349-3361.
    >> Share

  16. FU CK, Chang WS, Tsai CW, Wang YC, et al
    The Association of MMP9 Promoter Rs3918242 Genotype With Gastric Cancer.
    Anticancer Res. 2021;41:3309-3315.
    >> Share

    June 2021
  17. ARIGAMI T, Matsushita D, Okubo K, Sasaki K, et al
    Prognostic Significance of HER2 Expression for Gastric Cancer With Clinically Para-aortic Lymph Node Metastasis.
    Anticancer Res. 2021;41:3099-3107.
    >> Share

    May 2021
  18. TSAI CY, Liu KH, Chiu CT, Hsueh SW, et al
    Alpha-fetoprotein for Gastric Cancer Staging: An Essential or Redundant Tumor Marker?
    Anticancer Res. 2021;41:2711-2718.
    >> Share

  19. TAKAO K, Konishi H, Matsubara D, Shoda K, et al
    MiR-3663-3p Inhibits the Progression of Gastric Cancer Through the CCND1 Pathway.
    Anticancer Res. 2021;41:2441-2449.
    >> Share

    April 2021
  20. JIN YZ, Gong YX, Liu Y, Xie DP, et al
    Peroxiredoxin V Silencing Elevates Susceptibility to Doxorubicin-induced Cell Apoptosis via ROS-dependent Mitochondrial Dysfunction in AGS Gastric Cancer Cells.
    Anticancer Res. 2021;41:1831-1840.
    >> Share

    March 2021
  21. NAKANISHI Y, Hirota S, Hojo Y, Nakamura T, et al
    Pathological Complete Remission of Liver Metastases Correlates With Elimination of Tumor-infiltrating Tregs in Gastric Cancer.
    Anticancer Res. 2021;41:1571-1577.
    >> Share

  22. ZHANG X, Yamamoto Y, Wang X, Sato M, et al
    MDM4 as a Prognostic Factor for Patients With Gastric Cancer With Low Expression of p53.
    Anticancer Res. 2021;41:1475-1483.
    >> Share

    February 2021
  23. SHIMODA Y, Fujikawa H, Komori K, Watanabe H, et al
    Prognostic Factors for Gastric Cancer Patients With One Stage IV Factor who Underwent Conversion Surgery.
    Anticancer Res. 2021;41:1005-1012.
    >> Share

  24. SUZUKI O, Yamaguchi T, Fukuchi M, Mochiki E, et al
    Prediction Model for Gastric Cancer With DNA Mismatch Repair Deficiency.
    Anticancer Res. 2021;41:975-982.
    >> Share

  25. SASAHARA M, Kanda M, Shimizu D, Tanaka C, et al
    Tissue RNFT2 Expression Levels Are Associated With Peritoneal Recurrence and Poor Prognosis in Gastric Cancer.
    Anticancer Res. 2021;41:609-617.
    >> Share

    January 2021
  26. KIM EJ, Kim M, Seo S, Kim MJ, et al
    Comparison of Sinusoidal Obstruction Syndrome in Gastric Cancer Patients Receiving S-1/oxaliplatin Versus Capecitabine/oxaliplatin.
    Anticancer Res. 2021;41:391-402.
    >> Share

  27. LIM SC, Lee TB, Kang BS, Iy Han S, et al
    Extracellular Acidity-mediated Expression of cPLA2gamma Confers Resistance in Gastric Cancer Cells.
    Anticancer Res. 2021;41:211-218.
    >> Share

  28. LEE GH, Park JW, Roh J, Kim YB, et al
    Association Between Waiting Time from Diagnosis to Endoscopic Submucosal Dissection and Non-curative Resection in Gastric Neoplasm.
    Anticancer Res. 2021;41:459-466.
    >> Share

    December 2020
  29. FUJII H, Makiyama A, Iihara H, Okumura N, et al
    Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer.
    Anticancer Res. 2020;40:7067-7075.
    >> Share

  30. NAKAMURA S, Kanda M, Shimizu D, Tanaka C, et al
    AMIGO2 Expression as a Potential Prognostic Biomarker for Gastric Cancer.
    Anticancer Res. 2020;40:6713-6721.
    >> Share

    November 2020
  31. TRUMBULL D, Lemini R, Attwood K, Kukar M, et al
    Gastric Cancer Disparities Among Asian American Subpopulations.
    Anticancer Res. 2020;40:6381-6385.
    >> Share

  32. CHEN YC, Wu CC, Tu YT, Chen YR, et al
    Involvement of the MicroRNA-1-LITAF Axis in Gastric Cancer Cell Growth and Invasion.
    Anticancer Res. 2020;40:6247-6256.
    >> Share

  33. MAKI M, SOderstrOm D, Paloheimo L, Hendolin P, et al
    Helicobacter pylori (Hp) IgG ELISA of the New-Generation GastroPanel(R) Is Highly Accurate in Diagnosis of Hp-Infection in Gastroscopy Referral Patients.
    Anticancer Res. 2020;40:6387-6398.
    >> Share

    October 2020
  34. HASHIMOTO I, Oue N, Kimura Y, Hiroshima Y, et al
    Clinical Significance of Glioma-associated Oncogene 1 Expression in Patients With Locally Advanced Gastric Cancer Administered Adjuvant Chemotherapy With S-1 After Curative Surgery.
    Anticancer Res. 2020;40:5815-5821.
    >> Share

  35. ENDO S, Fujiwara Y, Yamatsuji T, Nishikawa K, et al
    Is it Necessary to Confirm Negative Margins in Gastrectomy for Peritoneal Lavage Cytology-positive Gastric Cancer?
    Anticancer Res. 2020;40:5807-5813.
    >> Share

  36. UEJIMA C, Morimoto M, Yamamoto M, Hara K, et al
    Prognostic Significance of TYRO3 Receptor Tyrosine Kinase Expression in Gastric Cancer.
    Anticancer Res. 2020;40:5593-5600.
    >> Share

  37. SUGISAWA N, Nishino H, Higuchi T, Park JH, et al
    A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy.
    Anticancer Res. 2020;40:5393-5397.
    >> Share

    August 2020
  38. KIM EY, Jun KH, Yim K
    The Roles of Connexin 26, 32, and 43 as Prognostic Factors for Gastric Cancer.
    Anticancer Res. 2020;40:4537-4545.
    >> Share

  39. KANAZAWA Y, Yamada T, Kakinuma D, Matsuno K, et al
    Skeletal Muscle Mass Depletion After Gastrectomy Negatively Affects the Prognosis of Patients With Gastric Cancer.
    Anticancer Res. 2020;40:4271-4279.
    >> Share

    July 2020
  40. MAEZAWA Y, Aoyama T, Ju M, Komori K, et al
    The Impact of Severe Infectious Complications on Long-term Prognosis for Gastric Cancer.
    Anticancer Res. 2020;40:4067-4074.
    >> Share

    June 2020
  41. KIM DS, Min K, Lee SK
    Cell Cycle Dysregulation Is Associated With 5-Fluorouracil Resistance in Gastric Cancer Cells.
    Anticancer Res. 2020;40:3247-3254.
    >> Share

  42. YANG JW, Lee JH, Lee JS, Kim DC, et al
    Characteristics of Gastric Carcinomas With High ERCC1 Expression and the Prognostic Value of ERCC1 Expression.
    Anticancer Res. 2020;40:3203-3208.
    >> Share

  43. KUBOTA T, Shoda K, Ogawa S, Matsumoto T, et al
    Oncological Safety of Ultrasonically Activated Surgical Devices During Gastric Cancer Surgery.
    Anticancer Res. 2020;40:3163-3167.
    >> Share

  44. DI GIROLAMO M, Carbonetti F, Bonome P, Grossi A, et al
    Hydro-MDCT for Gastric Adenocarcinoma Staging. A Comparative Study With Surgical and Histopathological Findings for Selecting Patients for Echo-endoscopy.
    Anticancer Res. 2020;40:3401-3410.
    >> Share

  45. TUNG KL, Wu YT, Liu C, Lin SC, et al
    EBV Rta-induced IL-6 Promotes Migration of Bystander Tumor Cells Through IL-6R/JAK/STAT3 Pathway In Vitro.
    Anticancer Res. 2020;40:3255-3264.
    >> Share

    May 2020
  46. ILLUMINATI G, Pasqua R, Nardi P, Fratini C, et al
    Resection for Internal Jugular Vein Thrombosis and Cervical Lymph Nodes' Involvement from Gastric Cancer.
    Anticancer Res. 2020;40:2889-2893.
    >> Share

    April 2020
  47. ENDO S, Ikenaga M, Yamada T, Tamura S, et al
    Prognostic Factors for Para-aortic Lymph Node Dissection After Neoadjuvant Chemotherapy for Gastric Cancer.
    Anticancer Res. 2020;40:2351-2357.
    >> Share

  48. KATO K, Narita Y, Mitani S, Honda K, et al
    Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer.
    Anticancer Res. 2020;40:2247-2255.
    >> Share

  49. BRAEUER F, Fischer I, Brammen L, Pressl G, et al
    Outcome in Patients Treated With Cytoreductive Surgery and HIPEC for Gastric Cancer With Peritoneal Carcinomatosis.
    Anticancer Res. 2020;40:2151-2156.
    >> Share

  50. KIM HB, Lee HJ, Kim GB, Lim HJ, et al
    Clinical Significance of Jagged-1 Activated by APEX1 as a Chemoresistance Factor in Advanced Gastric Cancer.
    Anticancer Res. 2020;40:1897-1904.
    >> Share

  51. SHIMODA Y, Yamada T, Komori K, Watanabe H, et al
    Effect of Muscle Mass Loss After Esophagectomy on Prognosis of Oesophageal Cancer.
    Anticancer Res. 2020;40:2275-2281.
    >> Share

    March 2020
  52. VIRGILIO E, Proietti A, D'Urso R, Cardelli P, et al
    Elevated Gastric Juice Carbohydrate Antigen 72.4 (Ca 72.4) Is an Independent Prognostic Factor of Poor Survival for Gastric Cancer Patients.
    Anticancer Res. 2020;40:1691-1695.
    >> Share

  53. WATANABE H, Hayashi T, Komori K, Hara K, et al
    Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1.
    Anticancer Res. 2020;40:1683-1690.
    >> Share

  54. HARA K, Aoyama T, Yamada T, Nakazono M, et al
    The Prognostic Value of the Perioperative Systemic Inflammation Score for Patients With Advanced Gastric Cancer.
    Anticancer Res. 2020;40:1503-1512.
    >> Share

  55. MIGITA K, Matsumoto S, Wakatsuki K, Kunishige T, et al
    RNF126 as a Marker of Prognosis and Proliferation of Gastric Cancer.
    Anticancer Res. 2020;40:1367-1374.
    >> Share

    February 2020
  56. SAWASAKI M, Tsubamoto H, Nakamoto Y, Kakuno A, et al
    S-1, Oxaliplatin, Nab-paclitaxel and Itraconazole for Conversion Surgery for Advanced or Recurrent Gastric Cancer.
    Anticancer Res. 2020;40:991-997.
    >> Share

  57. LEMINI R, Jorgensen MS, Attwood K, Almerey T, et al
    Racial Disparities in Outcomes Among Asians With Gastric Cancer in the USA.
    Anticancer Res. 2020;40:881-889.
    >> Share

  58. FU CK, Chien YC, Chuang HY, Wang YC, et al
    The Association of MMP7 Promoter Polymorphisms With Gastric Cancer.
    Anticancer Res. 2020;40:695-702.
    >> Share

  59. AURELLO P, Cinquepalmi M, Petrucciani N, Moschetta G, et al
    Impact of Anastomotic Leakage on Overall and Disease-free Survival After Surgery for Gastric Carcinoma: A Systematic Review.
    Anticancer Res. 2020;40:619-624.
    >> Share

  60. BAUMGARTNER R, Taghizadeh H, Jomrich G, Schoppmann SF, et al
    Utilization and Efficacy of Palliative Chemotherapy for Locally Advanced or Metastatic Gastroesophageal Carcinoma.
    Anticancer Res. 2020;40:965-975.
    >> Share

    January 2020
  61. TAMAGAWA H, Aoyama T, Kano K, Numata M, et al
    The Impact of Intraoperative Blood Loss on the Long-term Prognosis after Curative Resection for Borrmann Type IV Gastric Cancer: A Retrospective Multicenter Study.
    Anticancer Res. 2020;40:405-412.
    >> Share

  62. YOO HJ, Kim TJ, Kim DJ, Kim W, et al
    Role of COX2 as a Biomarker for Estimating Survival of Patients With Clinical Stage I Gastric Cancer.
    Anticancer Res. 2020;40:341-347.
    >> Share

  63. ISHIKAWA D, Yoshikawa K, Takasu C, Kashihara H, et al
    Expression Level of MicroRNA-449a Predicts the Prognosis of Patients With Gastric Cancer.
    Anticancer Res. 2020;40:239-244.
    >> Share

  64. TAKANO Y, Shida A, Fujisaki M, Mitsumori N, et al
    Prognostic Significance of ZKSCAN3 (ZNF306) Expression in Gastric Carcinoma.
    Anticancer Res. 2020;40:81-86.
    >> Share

  65. KIJIMA T, Arigami T, Uenosono Y, Hiraki T, et al
    Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer.
    Anticancer Res. 2020;40:75-80.
    >> Share

    December 2019
  66. BAEK JH, Park DJ, Kim GY, Cheon J, et al
    Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer.
    Anticancer Res. 2019;39:6973-6979.
    >> Share

  67. KOSUGA T, Konishi T, Kubota T, Shoda K, et al
    Value of Prognostic Nutritional Index as a Predictor of Lymph Node Metastasis in Gastric Cancer.
    Anticancer Res. 2019;39:6843-6849.
    >> Share

  68. YAMAMOTO Y, Kuroda K, Sera T, Sugimoto A, et al
    The Clinicopathological Significance of the CXCR2 Ligands, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 in Gastric Cancer.
    Anticancer Res. 2019;39:6645-6652.
    >> Share

  69. ONEYAMA M, Sakamoto N, Oue N, Kimura Y, et al
    Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug Therapy.
    Anticancer Res. 2019;39:6567-6573.
    >> Share

  70. KIM JS, Bae GE, Kim KH, Lee SI, et al
    Prognostic Significance of LC3B and p62/SQSTM1 Expression in Gastric Adenocarcinoma.
    Anticancer Res. 2019;39:6711-6722.
    >> Share

    November 2019
  71. NAEEM B, Ayub A
    Primary Pediatric Non-Hodgkin Lymphomas of the Gastrointestinal Tract: A Population-based Analysis.
    Anticancer Res. 2019;39:6413-6416.
    >> Share

  72. TAKAHASHI Y, Fukuyama T, Futawatari N, Ichiki Y, et al
    Expression of Kita-Kyushu Lung Cancer Antigen-1 as Detected by a Novel Monoclonal Antibody in Gastric Cancer.
    Anticancer Res. 2019;39:6259-6263.
    >> Share

  73. ENDO S, Nishikawa K, Fujitani K, Matsuyama J, et al
    Is D2 Lymphadenectomy Essential for Cytology-positive Gastric Cancer? A Retrospective Analysis.
    Anticancer Res. 2019;39:6209-6216.
    >> Share

  74. SAWAKI K, Kanda M, Umeda S, Miwa T, et al
    Level of Melanotransferrin in Tissue and Sera Serves as a Prognostic Marker of Gastric Cancer.
    Anticancer Res. 2019;39:6125-6133.
    >> Share

  75. NAKATA S, Fujita M, Nakanishi H
    Efficacy of Afatinib and Lapatinib Against HER2 Gene-amplified Trastuzumab-sensitive and -resistant Human Gastric Cancer Cells.
    Anticancer Res. 2019;39:5927-5932.
    >> Share

  76. ENDO M, Kanda M, Sawaki K, Shimizu D, et al
    Tissue Expression of Melanoma-associated Antigen A6 and Clinical Characteristics of Gastric Cancer.
    Anticancer Res. 2019;39:5903-5910.
    >> Share

  77. KHING TM, Po WW, Sohn UD
    Fluoxetine Enhances Anti-tumor Activity of Paclitaxel in Gastric Adenocarcinoma Cells by Triggering Apoptosis and Necroptosis.
    Anticancer Res. 2019;39:6155-6163.
    >> Share

    October 2019
  78. YU JI, Lim DH, Lee J, Kang WK, et al
    Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (</=45 Years) With Gastric Cancer.
    Anticancer Res. 2019;39:5811-5820.
    >> Share

  79. HASHIMOTO I, Sakamaki K, Oue N, Kimura Y, et al
    Clinical Significance of PRKCI Gene Expression in Cancerous Tissue in Patients With Gastric Cancer.
    Anticancer Res. 2019;39:5715-5720.
    >> Share

  80. TSAI KW, Tsai CY, Chou NH, Wang KC, et al
    Aberrant DNA Hypermethylation Silenced LncRNA Expression in Gastric Cancer.
    Anticancer Res. 2019;39:5381-5391.
    >> Share

    September 2019
  81. WOLL E, Eisterer W, Gerger A, Kuhr T, et al
    Treatment Algorithm for Patients With Gastric Adenocarcinoma: An Austrian Consensus on Systemic Therapy.
    Anticancer Res. 2019;39:4589-4596.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016